Last updated: 06/18/2019 10:00:25
Study to Evaluate the Effectiveness of Rotarix™ Against Severe Gastroenteritis Among Hospitalized Children in Brazil
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Case-control Study to Evaluate the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalized Children Born After 6 March 2006 and at Least 12 Weeks of Age, in Belem, Brazil
Trial description: The purpose of this study is to estimate the effectiveness of 2 doses of Rotarix™ vaccination in preventing rotavirus severe gastroenteritis among children hospitalized in Belem area, Brazil.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Risk of Enzyme Linked Immunosorbent Assay (ELISA) confirmed rotavirus severe gastroenteritis in children fully vaccinated with Rotarix™, compared to risk of ELISA confirmed rotavirus severe gastroenteritis in unvaccinated children
Timeframe: Average time frame: 12-24 months
Secondary outcomes:
Risk of ELISA confirmed rotavirus severe gastroenteritis in children vaccinated with at least one dose of Rotarix™, compared to risk of ELISA confirmed rotavirus severe gastroenteritis in unvaccinated children
Timeframe: Average time frame: 12-24 months
Occurrence of severe gastroenteritis among children admitted to study clinics/hospitals for severe gastroenteritis
Timeframe: Average time frame: 12-24 months
Occurrence of rotavirus serotypes among children
Timeframe: Average time frame: 36 months
Interventions:
Enrollment:
1944
Primary completion date:
2011-11-05
Observational study model:
Case-Control
Time perspective:
Prospective
Clinical publications:
Justino MC et al. (2011) Effectiveness of the Monovalent G1P[8] Human Rotavirus Vaccine Against Hospitalization for Severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil. Pediatr Infect Dis J. 30(5):396-401.
Guerra SF et al. (2015) Rotavirus strain surveillance for three years following the introduction of rotavirus vaccine into Belém, Brazil. J Med Virol. 87(8):1303-1310.
Medical condition
Rotavirus gastroenteritis
Product
SB444563
Collaborators
Not applicable
Study date(s)
May 2008 to May 2011
Type
Observational
Phase
4
Participation criteria
Sex
Female & Male
Age
12+ years
Accepts healthy volunteers
No
- For cases:
- A male or female child born after 6 March 2006 and at least 12 weeks of age.
- For cases:
- Subject has previously participated as case or control in this study.
Inclusion and exclusion criteria
Inclusion criteria:
- For cases:
- A male or female child born after 6 March 2006 and at least 12 weeks of age.
- Subject admitted to the study clinics/hospitals for severe gastroenteritis during the study period.
- Onset of severe gastroenteritis ≤ 14 days prior to admission.
- Laboratory confirmed rotavirus positive stool sample at hospital admission or during the first 48 hours of hospitalization.
- Written informed consent obtained from the parent or guardian of the subject. For controls:
- Admitted for non-gastroenteritis causes at the same clinic/hospital as the case.
- Living in the same neighbourhood as the case for at least three consecutive months without any symptoms of gastroenteritis or severe gastroenteritis on the day of interview of his/ her parents/ guardians.
- Being born within +- 2 weeks from the date of birth of the case. If the number required is not available, then the range would be extended to +- 4 weeks, and ultimately up to +- 6 weeks for hospital controls. For neighbourhood controls, the range may be extended to +- 8 weeks.
- Written informed consent obtained from the parent or guardian of the child.
Exclusion criteria:
- For cases:
- Subject has previously participated as case or control in this study.
- Onset of severe gastroenteritis > 48 hours after admission to the hospital (nosocomial infections). For controls:
- For hospital controls: Child who has symptoms of gastroenteritis during current hospitalization or on the day of interview of his/her parent or guardian or for neighbourhood controls: Child who has symptoms of gastroenteritis or severe gastroenteritis on the day of interview of his/her parent or guardian.
- Exclude children with the following vaccine preventable diseases: measles, mumps, rubella, diphtheria, pertussis, tetanus, tuberculosis, invasive Haemophilus influenzae type B (Hib) infections (meningitis, bacteraemia, septic arthritis, cellulitis, and epiglottitis) and hepatitis B.
- Child has participated in the past as a case or control in this study.
- Child living in the same house as the case
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
Clinical study report
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
2011-11-05
Actual study completion date
2011-11-05
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website